Fundraising Fox

Crescendo Biologics

11 known investors

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology. The company collaborates with major pharmaceutical partners including BioNTech and Takeda on drug discovery and development.

BiotechHealthtechMedical Devices

Investors · 11

Andera Partners✓ verifiedParis
Quan Capital✓ verifiedShanghai
Sofinnova Partners✓ verifiedParis · $540K – $27M
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
EMBL VenturesHeidelberg · $108K – $5.4M
Future Planet CapitalLondon
Avlar BioVenturesreportedMadingley
Kreos Capitalreported · 2 sourcesLondon

Also in the syndicate · 3

BioNTechIP GroupTakeda

In the news

Crescendo Biologics raises $32M and expands cancer triallabiotech.eu · Jul 2023Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing - BioSpacebiospace.com · Apr 2018Crescendo raises $70M to trial bispecific T-cell engager | Fierce Biotechfiercebiotech.com · Apr 2018Crescendo Biologics Raises £17.5M ($28M) in Series A Financingprnewswire.com · Dec 2013UK, Crescendo Biologics Raises £4.5M in Seed-Funding Round - FinSMEsfinsmes.com · Oct 2009Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners | Fierce Biotechfiercebiotech.com · Oct 2009

Frequently asked questions

What does Crescendo Biologics do?
Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology. The company collaborates with major pharmaceutical partners including BioNTech and Takeda on drug discovery and development.
Who are Crescendo Biologics's investors?
Crescendo Biologics's investors include Andera Partners, Quan Capital, Sofinnova Partners, Astellas Venture Management LLC, EMBL Ventures, Future Planet Capital, Avlar BioVentures, Kreos Capital.